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Background: Hyperthyroidism is a common endocrine disorder with multi-systemic effects, the least reported of which is bone
loss and fractures.
Objective: The aim was to evaluate the risk factors, pattern and frequency of bone fractures among Nigerians with
hyperthyroidism.
Methodology: An analytical study was undertaken of 40 patients with hyperthyroidism aged between 21 and 50 years. They
were seen at the outpatient Endocrine, Diabetic and Metabolism (EDM) clinic of Lagos State University Teaching Hospital
(LASUTH). Using an interviewer-administered questionnaire, information on sociodemographics, medical history, clinical and
biochemical parameters and dual-energy X-ray absorptiometry (DXA) scan was obtained. Risk of fracture was assessed using
WHO and ISCD risk calculators. During statistical analysis, quantitative and qualitative data were expressed as mean (SD) and
percentages.
Results: In all, 40 patients with hyperthyroidism were studied with a mean age of 36.16 (8.43) years. There were 32 females (80%,
female:male ratio 4:1) and mean body mass index was 24.14 (4.3) kg/m. Hyperthyroidism was defined by Waynes’ scoring index
greater than 19 and confirmed by elevated thyroid hormones (FT4 39.44 (24.11) (pmol/l), FT3 12.13 (7.83) (pmol/l)) and
suppressed TSH 0.26 (0.03) (u/U/ml). Increased bone turnover was documented by elevated bone formation markers
(osteocalcin 45.7 (19.9) ng/ml and alkaline phosphatase 221.1 (143.46 IU/l)), bone resorption markers (24-hour calcium
excretion 590.95 (506.1) mg/day). The mean BMD T- and Z-scores were reduced –2.0 (1.2). Bone loss was observed in 31
(72.5%) hyperthyroid subjects, but only three (7.5%) had fractures due to minor trauma.
Conclusion: Bone fractures may not be uncommon in hyperthyroidism. Early screening for bone diseases should be encouraged
to improve treatment outcome.
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Introduction
Thyrotoxicosis is a clinical syndrome characterised by an
accelerated metabolism resulting from an excessive amount
of circulating thyroid hormones. It has multi-systemic manifes-
tations with clinical features ranging from silent to florid1
that may occur with signs of hyperactivity, including atrial
fibrillation—especially in the elderly, muscle weakness and
wasting, heart failure and if uncontrolled may lead to a
thyroid storm.
Common causes of hyperthyroidism include Graves’ disease,
toxic multinodular and solitary nodular goitre.
Thyroid hormones are essential for normal skeletal growth and
maintenance of bone mass.2 Excessive circulating thyroid hor-
mones may result in bone loss, which may manifest with bone
pains, trivial and stress fractures or hip fractures from acute
pressure.3 These bone changes are characterised by enhanced
bone turnover in both trabecular and cortical bone, leading to
increased porosity and mobilisation of bone mineral,4 though
the cortical bone is more commonly affected than trabecular
bone for which reason bone mineral density (BMD) is best
measured at the distal forearm in hyperthyroidism.5 These
bone changes of hyperthyroidism may or may not be reversible
with medical therapy, thereby putting patients at increased risk
of fractures.6
Correlating the two disease conditions of fractures and
hyperthyroidism may remain a dilemma and diagnostic chal-
lenge, especially among primary care physicians, since bone
loss in hyperthyroidism is a rarely reported complication in
sub-Saharan Africa. In addition, dual energy X-ray absorptiome-
try (DXA) scanning—the gold standard for the determination of
bone mineral density—is not accessible or available in our
environment of limited resources.
There are few reports on the prevalence, the pattern, the risk
assessment of fractures and the burden of hyperthyroidism
disease in Nigeria. This study therefore sought to evaluate
these factors among hyperthyroid patients at EDM clinic,
LASUTH.
Methodology
This was a descriptive analytical study carried out at the Endo-
crine, Diabetic and Metabolic unit run by the Department of
Internal Medicine, Lagos State University Teaching Hospital,
Ikeja (LASUTH) over a one-year period (2011).
All 40 patients who presented with clinical and biochemical fea-
tures of hyperthyroidism of more than 3 months’ duration were
included in the study. Ethical approval for the study was
obtained from HREC of LASUTH and signed informed consent
was obtained from each participant. Sociodemographic and
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other clinical data were collected using structured interviewer-
administered questionnaires. Only patients who met the
inclusion criteria were recruited. Exclusion criteria included:
chronic medical disorders, other secondary causes of osteoporo-
sis, history of childhood fractures, pregnancy, significant alcohol
intake (24 gm in a day) or smoking 20 packets per year, caffeine
intake, menopause, drug use (of oestrogen, thiazide diuretic,
calcium, for management of osteoporosis, and vitamin D) in
the last 12 months and the presence of proteinuria.
Fasting blood samples were drawn for biochemical and hormo-
nal assay, which included serum calcium, albumin, phosphorus,
creatinine, bone markers (osteocalcin and alkaline phosphatase
as bone formation markers), free thyroxine (FT4), free triio-
dothyronine (FT3), sensitive thyroid stimulating hormone
(sTSH), parathyroid hormone, 25-hydroxyvitamin D and 24-
hour calcium excretion as bone resorption marker. Early
morning urine was analysed for creatinine and phosphorus.
BMD, T- and Z-scores were determined using DXA Lunar Pixi
#50734 9 (http://www.bonedensitymachines.com).
Definition of terms
(1) Wayne’s index, a diagnostic tool to facilitate objectivity
and improve the accuracy of clinical assessment of
hyperthyroidism, is used to define symptoms and signs
of thyrotoxicosis. A score of 19 or more implies toxic
hyperthyroidism, score between 11 and 19 is equivocal,
while less than 11 is consistent with euthyroidism.7 Only
subjects with toxic hyperthyroidism were recruited. This
was confirmed by biochemical hyperthyroidism with
sTSH < 0.5 u/U/ml, fT4 > 22.0 pmol/l, fT3 > 6.5 pmol/l.7
(2) Increased bone turnover is defined by elevated bone for-
mation markers represented by alkaline phosphatase >
130 U/l,8 osteocalcin > 25.3 ng/ml9 and/or bone resorp-
tion markers as 24-hour calcium excretion > 4 mg/kg
per 24 hours.10
(3) The International Society of Clinical Densitometry (ISCD)
criteria defined osteoporosis Z-score < –2.0.11
The World Health Organization (WHO) criteria are
based on T-score up to −1.0 SD normal, −1.1 to −2.5 SD
osteopenia, and below <−2.5 SD osteoporosis.12
(4) Fracture risk calculator tools:
(a) FRAX calculation tool (WHOmodel): Assessment of frac-
ture risk is significant when the 10-year probability of
major clinical osteoporotic fracture (in spine, forearm,
hip or shoulder) is greater than 20%, and for hip fracture
greater than 3%.13
(b) International Society of Clinical Densitometry models:
Automatically calculates risk in reference to the age of
the patient. The FORE Fracture Risk Calculator (FRC)14
and Garvan Fracture Risk (GFR) calculator15 estimate
10-year fracture risk of hip fracture and any other
major osteoporotic fracture. In addition to convectional
10-year fracture risk assessment, Garvan et al. incorpor-
ated 5-year risk of both fracture types.
Statistical analysis
The data were analysed using the Statistical Package for the
Social Sciences (SPSS) Version 21.0 (IBM Corp, Armonk, NY,
USA) with quantitative data reported as means (+ standard devi-
ation), and qualitative data as percentages (%).
Result
The mean age of hyperthyroid patients was 36.13 (8.43) years; 32
(80%) were females while 8 (20%) were male and body mass
index (BMI) of subjects was 24.4 (4.34) kg/m2.
In this study, a significant number of hyperthyroid patients (19
[47.5%]) presented with a recurrent history of bone and joint
pains, cramps/spasms (62.5%) as well as proximal myopathy
(47.5%).
Furthermore, subjects demonstrated increased bone turnover
evidenced by elevated bone markers (osteocalcin, alkaline phos-
phatase and 24-hour urinary calcium excretion). The mean sera
calcium and phosphorus were within normal range (Table 1).
The BMD (g/cm2), T- and Z-score were reported for hyperthyroid
individuals. However, there was no significant difference in cor-
relation between T- and Z-score because the hyperthyroid sub-
jects were near their peak adult bone mass (see Table 1).
According to the BMD diagnosis, using WHO criteria showed
that 9 (22.5%) were normal, 19 (47.5%) had osteopenia and 12
(30%) had osteoporosis.
The 10-year probability of hip fracture and any other large
(major) osteoporotic fractures was calculated using different
fracture calculation tools. Hip fracture risk was documented as
follows: FRAX 16.6 (10.1), FORE 1.4 (1.2) and Garvan 17.2 (8.6)
and major osteoporotic fracture risk, FRAX 18.1(10.1), FORE 2.5
(1.6) and Garvan 25 (11.3).
A fracture was observed in three (7.5%) of the study subjects,
two (66.7%) of whom were females and had osteopenic frac-
tures, while the third had a low-normal T-score fracture. The
three hyperthyroid patients with fractures had hypocalcaemia,
hypophosphatemia and vitamin D insufficiency (Table 2).
Discussion
A large number of these hyperthyroid patients presented with
complaints of osteopenia in addition to the clinical character-
istics of thyrotoxicosis in the referral centres. They were investi-
gated and the diagnosis confirmed by biochemical parameters,
in addition to dual-energy X-ray absorptiometry. It is worth men-
tioning that both conditions were handled as different entities
by the general practitioners in the referring hospitals.





Corrected calcium (mmol/l) 2.3 (0.19)
Phosphorus (mmol/l) 1.43 (1.28)
Alkaline phosphatase (IU/l) 221.1 (143.46)
TSH (u/U/ml) 0.26 (0.03)
Free thyroxine (pmol/l) 39.44 (24.11)
Free triiodothyronine (pmol/l) 12.13 (7.83)
Osteocalcin (ng/ml) 45.7 (19.9)
25-hydroxyvitamin D (nmol/l) 56.56 (16.63)
Parathyroid hormone (pg/dl) 51.7 (5.37)
Urine:
24-hour Ur Ca Exc (mg/day) 590.95 (506.71)
24 -hour Ur Phos Excr (mg/day) 1471.35 (1667.56)
DXA:
T-/Z-score −2.0 (1.2)
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other clinical data were collected using structured interviewer-
administered questionnaires. Only patients who met the
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chronic medical disorders, other secondary causes of osteoporo-
sis, history of childhood fractures, pregnancy, significant alcohol
intake (24 gm in a day) or smoking 20 packets per year, caffeine
intake, menopause, drug use (of oestrogen, thiazide diuretic,
calcium, for management of osteoporosis, and vitamin D) in
the last 12 months and the presence of proteinuria.
Fasting blood samples were drawn for biochemical and hormo-
nal assay, which included serum calcium, albumin, phosphorus,
creatinine, bone markers (osteocalcin and alkaline phosphatase
as bone formation markers), free thyroxine (FT4), free triio-
dothyronine (FT3), sensitive thyroid stimulating hormone
(sTSH), parathyroid hormone, 25-hydroxyvitamin D and 24-
hour calcium excretion as bone resorption marker. Early
morning urine was analysed for creatinine and phosphorus.
BMD, T- and Z-scores were determined using DXA Lunar Pixi
#50734 9 (http://www.bonedensitymachines.com).
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(1) Wayne’s index, a diagnostic tool to facilitate objectivity
and improve the accuracy of clinical assessment of
hyperthyroidism, is used to define symptoms and signs
of thyrotoxicosis. A score of 19 or more implies toxic
hyperthyroidism, score between 11 and 19 is equivocal,
while less than 11 is consistent with euthyroidism.7 Only
subjects with toxic hyperthyroidism were recruited. This
was confirmed by biochemical hyperthyroidism with
sTSH < 0.5 u/U/ml, fT4 > 22.0 pmol/l, fT3 > 6.5 pmol/l.7
(2) Increased bone turnover is defined by elevated bone for-
mation markers represented by alkaline phosphatase >
130 U/l,8 osteocalcin > 25.3 ng/ml9 and/or bone resorp-
tion markers as 24-hour calcium excretion > 4 mg/kg
per 24 hours.10
(3) The International Society of Clinical Densitometry (ISCD)
criteria defined osteoporosis Z-score < –2.0.11
The World Health Organization (WHO) criteria are
based on T-score up to −1.0 SD normal, −1.1 to −2.5 SD
osteopenia, and below <−2.5 SD osteoporosis.12
(4) Fracture risk calculator tools:
(a) FRAX calculation tool (WHOmodel): Assessment of frac-
ture risk is significant when the 10-year probability of
major clinical osteoporotic fracture (in spine, forearm,
hip or shoulder) is greater than 20%, and for hip fracture
greater than 3%.13
(b) International Society of Clinical Densitometry models:
Automatically calculates risk in reference to the age of
the patient. The FORE Fracture Risk Calculator (FRC)14
and Garvan Fracture Risk (GFR) calculator15 estimate
10-year fracture risk of hip fracture and any other
major osteoporotic fracture. In addition to convectional
10-year fracture risk assessment, Garvan et al. incorpor-
ated 5-year risk of both fracture types.
Statistical analysis
The data were analysed using the Statistical Package for the
Social Sciences (SPSS) Version 21.0 (IBM Corp, Armonk, NY,
USA) with quantitative data reported as means (+ standard devi-
ation), and qualitative data as percentages (%).
Result
The mean age of hyperthyroid patients was 36.13 (8.43) years; 32
(80%) were females while 8 (20%) were male and body mass
index (BMI) of subjects was 24.4 (4.34) kg/m2.
In this study, a significant number of hyperthyroid patients (19
[47.5%]) presented with a recurrent history of bone and joint
pains, cramps/spasms (62.5%) as well as proximal myopathy
(47.5%).
Furthermore, subjects demonstrated increased bone turnover
evidenced by elevated bone markers (osteocalcin, alkaline phos-
phatase and 24-hour urinary calcium excretion). The mean sera
calcium and phosphorus were within normal range (Table 1).
The BMD (g/cm2), T- and Z-score were reported for hyperthyroid
individuals. However, there was no significant difference in cor-
relation between T- and Z-score because the hyperthyroid sub-
jects were near their peak adult bone mass (see Table 1).
According to the BMD diagnosis, using WHO criteria showed
that 9 (22.5%) were normal, 19 (47.5%) had osteopenia and 12
(30%) had osteoporosis.
The 10-year probability of hip fracture and any other large
(major) osteoporotic fractures was calculated using different
fracture calculation tools. Hip fracture risk was documented as
follows: FRAX 16.6 (10.1), FORE 1.4 (1.2) and Garvan 17.2 (8.6)
and major osteoporotic fracture risk, FRAX 18.1(10.1), FORE 2.5
(1.6) and Garvan 25 (11.3).
A fracture was observed in three (7.5%) of the study subjects,
two (66.7%) of whom were females and had osteopenic frac-
tures, while the third had a low-normal T-score fracture. The
three hyperthyroid patients with fractures had hypocalcaemia,
hypophosphatemia and vitamin D insufficiency (Table 2).
Discussion
A large number of these hyperthyroid patients presented with
complaints of osteopenia in addition to the clinical character-
istics of thyrotoxicosis in the referral centres. They were investi-
gated and the diagnosis confirmed by biochemical parameters,
in addition to dual-energy X-ray absorptiometry. It is worth men-
tioning that both conditions were handled as different entities
by the general practitioners in the referring hospitals.
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Population and case-control studies reported hyperthyroidism
onset above age 50 years as an independent risk factor for hip
and vertebral fractures,16,17 and was also a cause of excess mor-
tality in previous hyperthyroid patients.18 While most of those
studies were performed in the older population, our study
involved patients with overt hyperthyroidism below the age of
50 years because hyperthyroidism is more commonly seen in
the third to fifth decades of life in this part of the world and
therefore it is pertinent also to evaluate the extent of bone
loss and fracture risk in this age group within our community.
The bony skeleton is a metabolically active organ that under-
goes continuous remodelling throughout life by dual and
coupled activities of bone resorption and formation,19 tightly
coupled in a temporal and spatial sequence to ensure the main-
tenance of skeletal mass and integrity.20 Remodelling is necess-
ary to maintain both the structural integrity of the skeleton and
also to perform metabolic functions as a storehouse of calcium
and phosphorus.20
In hyperthyroidism, the bone remodelling cycle is shortened; the
duration of resorption remains largely unaltered with the dur-
ation of bone formation reduced significantly. This leads to a
failure to replace resorbed bone completely, resulting in a net
loss of about 10% of mineralised bone per cycle21 making
bone loss a common feature of overt hyperthyroidism. This
results from accelerated bone remodelling, and reduced bone
density could lead to osteoporosis and an increase in fracture
rate as evidenced by an increase in the bone markers.22
The mean BMD, T- and Z-scores of our subjects were reduced.
This is consistent with a number of similar prospective
studies22–24 that reported low bone mass as an important risk
factor for fractures. In this study, bone loss of 77.5% (osteoporo-
sis and osteopenia) was recorded. However, none of the patients
with fractures in this study fell into the ISCD osteoporosis classi-
fication. Therefore, there is a need to re-stratify our study using
WHO criteria, which is consistent with a previous study24 in
which the lower the Z-score, the greater the risk of fracture.
There is a high fracture risk in hyperthyroidism. The limitations of
these calculator models are that they were developed from
studying population-based cohorts from Europe, North
America, Asia and Australia but not in African black individuals,
the age limits of these models and the specificity of BMD. These
calculators should be modified with the inclusion of the distal
radius because cortical tissues are predominantly affected
more than trabecular bone (abundant in the spine or femora)
in hyperthyroid patients and also age entry should be lower,
maybe from 30 years upwards.
Though low bone mineral density (BMD) may be a major con-
tributory factor to fracture risk, non-BMD risk factors16 that
increase the fracture risk of osteopenia in our study include
low BMI, weight loss, low serum calcium and vitamin D insuffi-
ciency. These factors contributed significantly to fracture risk
in our studied population.
The occurrence of fractures was observed in only a few of our
subjects, though the frequency may be higher as many fractures
may have passed unnoticed. There are reports of about two-
thirds of fractures being asymptomatic and diagnosed as an inci-
dental finding on X-ray.25 Two of the three were significant frac-
tures; two of the patients had osteopenia (−1.2 and −1.7) and
the third patient had a normal T-score of −0.4, although this is
at least −0.4 SD below the score expected for age and sex.
This may be indicative that low bone mass is a critical factor
for fractures, with values of bone mass in patients with fractures
overlapping substantially with values in those with no fractures,
and it has been argued that measurement of bone mass is not
helpful.26 In most studies, however, a decrease of 1 SD in
bone mass has been associated with an increase of 50–100%
incidence of fractures.26
The pattern of fractures in our hyperthyroid subjects involved
bones predominantly made up of cortical bone tissue confirmed
by pattern and sites of fractures. These are in the left lower third
of the tibia, left lower third of the radius (left forearm)/Colles
fracture, left distal phalanx of the fourth toe or left index
finger following minor trauma. This is in conformity with the
finding in a previous study of cortical involvement more than
trabecular bone.5
Neither age or sex was protective against fractures among the
study subjects, though there are reports of fractures being
common in older age groups, and post-menopausal females
when the protective effect of oestrogen is quite reduced.27,28
There are studies suggesting that skeletal changes of hyperthyr-
oidism could result from elevated T3 or TSH levels through
action on either osteoblastic or osteoclastic activities.21,29,30
Other contributory factors are increased serum interleukin –6
Table 2: Characteristics of hyperthyroid patients with fractures
Variables Case 1 Case 2 Case 3 Normal range
Serum calcium corrected (mmol/l) 1.8 1.9 2.0 2.15–2.55
Serum phosphorus 0.8 0.7 0.7 0.8–2.0
Alkaline phosphatase (IU/l) 215 263 222 9.0–130
Serum creatinine (umol/l) 54 46 62 55–115
Calcium excretion (mg/kg/day)
(osteoclastic activity)
752 825 957 4 mg/kg
Free thyroxine (pmol/l) 27.1 27.5 36.1 12.0–22.0
Free triiodothyronine (pmol/l) 8.4 14.6 11.7 3.0–6.5
Thyroid stimulating hrmone (u/U/ml) 0.27 0.28 0.25 0.54–3.7
Osteocalcin (ng/ml) 27.5 50 29 3.8–25.3
25-hydroxyvitaminD (nmol/l) 40 40 42 75–250
Parathyroid hormone (pg/dl) 12 12 17 10–65
DXA g/cm2
T-score/Z-score
0.385–1.7 0.456–1.2 0.467–0.4 -> −1
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levels, B-adrenergic receptor-mediated acceleration of bone
activation frequency and bone loss due to the increased sym-
pathetic tone that inhibits osteoblastic proliferation and bone
formation.31 Though these patients are on anti-thyroid therapy
and the beneficiary effect of anti-thyroid medications cannot
be overemphasised, patients’ thyrotoxic state was still uncon-
trolled. Longitudinal studies of patients successfully treated for
thyrotoxicosis had reported conflicting results, with the sugges-
tion that thyrotoxic bone loss may be potentially reversible.32,33
The mainstay of treating hyperthyroidism is medical therapy
with thiourea, i.e carbimazole, radio-iodine ablation and surgical
management by partial or total thyroidectomy.
A previous study in Nigerians among hyperthyroid patients has
documented an osteoporosis rate of 45%.34 Hyperthyroidism is
an established risk factor of secondary osteoporosis, and an
increased fracture risk as documented by this study.
For a better management outcome, fractures must be managed
in association with the thyrotoxic state to improve quality of life,
and to reduce the physical disability associated with the burden
of the disease and the financial consequences. Therefore,
patients with spontaneous or mild fractures should be screened
for thyroid diseases or vice versa. Early diagnosis and prompt
management of the thyrotoxic state is essential with early
screening for bone-related complications.
Conclusion
Fractures may not be uncommon in hyperthyroidism in this age
group. Patients who have fractures should undergo screening
for thyroid disease. Risk factors contributory to fractures in
hyperthyroidism include low BMI, weight loss and vitamin D
insufficiency in addition to reduced bone mineral density.
Recommendation
Early diagnosis and prompt management of a thyrotoxic state
are imperative with early screening for bone-related compli-
cations to be incorporated into evaluation to reduce morbidity
and improve patient outcome.
Disclosure statement
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